PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29710490-6 2018 Furthermore, a proton beam suppressed TPA-induced gene expressions of urokinase plasminogen activator (uPA), uPA receptor (uPAR), Snail-1 and vascular endothelial growth factor (VEGF) in HepG2 cells in a dose-dependent manner. Tetradecanoylphorbol Acetate 38-41 vascular endothelial growth factor A Homo sapiens 142-176 31343893-6 2019 BABP inhibits phorbol 12-myristate 13-acetate (PMA)-induced matrix metalloproteinase (MMP) expression and activity by blocking mitogen-activated protein kinases (MAPKs) and NF-kappaB signaling and hypoxia-induced vascular endothelial growth factor (VEGF) secretion and hypoxia inducible factor (HIF)-1alpha accumulation through suppressing the AKT/mTOR signal pathway. Tetradecanoylphorbol Acetate 14-45 vascular endothelial growth factor A Homo sapiens 213-247 31343893-6 2019 BABP inhibits phorbol 12-myristate 13-acetate (PMA)-induced matrix metalloproteinase (MMP) expression and activity by blocking mitogen-activated protein kinases (MAPKs) and NF-kappaB signaling and hypoxia-induced vascular endothelial growth factor (VEGF) secretion and hypoxia inducible factor (HIF)-1alpha accumulation through suppressing the AKT/mTOR signal pathway. Tetradecanoylphorbol Acetate 14-45 vascular endothelial growth factor A Homo sapiens 249-253 31343893-6 2019 BABP inhibits phorbol 12-myristate 13-acetate (PMA)-induced matrix metalloproteinase (MMP) expression and activity by blocking mitogen-activated protein kinases (MAPKs) and NF-kappaB signaling and hypoxia-induced vascular endothelial growth factor (VEGF) secretion and hypoxia inducible factor (HIF)-1alpha accumulation through suppressing the AKT/mTOR signal pathway. Tetradecanoylphorbol Acetate 47-50 vascular endothelial growth factor A Homo sapiens 213-247 31343893-6 2019 BABP inhibits phorbol 12-myristate 13-acetate (PMA)-induced matrix metalloproteinase (MMP) expression and activity by blocking mitogen-activated protein kinases (MAPKs) and NF-kappaB signaling and hypoxia-induced vascular endothelial growth factor (VEGF) secretion and hypoxia inducible factor (HIF)-1alpha accumulation through suppressing the AKT/mTOR signal pathway. Tetradecanoylphorbol Acetate 47-50 vascular endothelial growth factor A Homo sapiens 249-253 29710490-8 2018 Therefore, the result demonstrates that the anti-metastatic effects of a proton beam in TPA-treated HepG2 cells are associated with the inhibition of MMP-9 activity and the down-regulations of MMP-9, uPA, uPAR, Snail-1 and VEGF gene expression via the p38 MAPK/c-Fos signaling pathway. Tetradecanoylphorbol Acetate 88-91 vascular endothelial growth factor A Homo sapiens 223-227 29710490-6 2018 Furthermore, a proton beam suppressed TPA-induced gene expressions of urokinase plasminogen activator (uPA), uPA receptor (uPAR), Snail-1 and vascular endothelial growth factor (VEGF) in HepG2 cells in a dose-dependent manner. Tetradecanoylphorbol Acetate 38-41 vascular endothelial growth factor A Homo sapiens 178-182 25941985-4 2015 Treatment with CPT also downregulated phorbol-12-myristate-13-acetate (PMA)- and tumor necrosis factor-alpha (TNF-alpha)-induced MMP-9 and VEGF expression by inhibiting nuclear factor-kappaB (NF-kappaB) activity. Tetradecanoylphorbol Acetate 38-69 vascular endothelial growth factor A Homo sapiens 139-143 25865025-5 2016 Human umbilical vein endothelial cell (HUVEC) cultures were stimulated to express VEGF by 10 nM phorbol-12-myristate 13-acetate (PMA). Tetradecanoylphorbol Acetate 96-127 vascular endothelial growth factor A Homo sapiens 82-86 25865025-5 2016 Human umbilical vein endothelial cell (HUVEC) cultures were stimulated to express VEGF by 10 nM phorbol-12-myristate 13-acetate (PMA). Tetradecanoylphorbol Acetate 129-132 vascular endothelial growth factor A Homo sapiens 82-86 26377185-5 2015 The contribution of the conventional Gi/Go, Gz and AKT/beta-Arrestin pathways in the VEGF regulation was assessed by adding pertussis toxin (PTX), phorbol 12-myristate 13-acetate (PMA), or wortmannin (WT). Tetradecanoylphorbol Acetate 180-183 vascular endothelial growth factor A Homo sapiens 85-89 25941985-4 2015 Treatment with CPT also downregulated phorbol-12-myristate-13-acetate (PMA)- and tumor necrosis factor-alpha (TNF-alpha)-induced MMP-9 and VEGF expression by inhibiting nuclear factor-kappaB (NF-kappaB) activity. Tetradecanoylphorbol Acetate 71-74 vascular endothelial growth factor A Homo sapiens 139-143 25941985-6 2015 We further confirmed that CPT inhibits PMA-induced MMP-9 and VEGF expression by upregulating nuclear factor-erythroid related factor-2 (Nrf2)-mediated heme oxygenase-1 (HO-1) induction. Tetradecanoylphorbol Acetate 39-42 vascular endothelial growth factor A Homo sapiens 61-65 25244493-8 2014 Inhibition of ERK activation blocks phorbol myristate acetate-induced MMP-9 activity and VEGF-A secretion in vitro. Tetradecanoylphorbol Acetate 36-61 vascular endothelial growth factor A Homo sapiens 89-95 25884029-7 2015 VEGF and IL-8 correlated positively with LDH and PAI-1/tPA ratio and negatively with tPA in both loculated and nonloculated TBPE. Tetradecanoylphorbol Acetate 55-58 vascular endothelial growth factor A Homo sapiens 0-4 25884029-7 2015 VEGF and IL-8 correlated positively with LDH and PAI-1/tPA ratio and negatively with tPA in both loculated and nonloculated TBPE. Tetradecanoylphorbol Acetate 85-88 vascular endothelial growth factor A Homo sapiens 0-4 23648122-8 2013 Conditioned media of five ESCC cell lines (TE-8, -9, -10, -11 and -15) induced mRNA as well as protein expression of CD204 but not of CD163 with upregulation of vascular endothelial growth factor-A mRNA in TPA treated human acute monocytic leukemia cell line THP-1. Tetradecanoylphorbol Acetate 206-209 vascular endothelial growth factor A Homo sapiens 161-197 24089228-13 2013 It was noteworthy that the ERK activator (phorbol 12-myristate 13-acetate [PMA]) treatment increased the MMP-9/VEGF levels after propofol treatment, and led to significant increase of proliferation, invasion and angiogenesis. Tetradecanoylphorbol Acetate 42-73 vascular endothelial growth factor A Homo sapiens 111-115 24089228-13 2013 It was noteworthy that the ERK activator (phorbol 12-myristate 13-acetate [PMA]) treatment increased the MMP-9/VEGF levels after propofol treatment, and led to significant increase of proliferation, invasion and angiogenesis. Tetradecanoylphorbol Acetate 75-78 vascular endothelial growth factor A Homo sapiens 111-115 23308155-8 2013 VEGF, IL-8 and effusion size correlated positively with PAI-1/tPA ratio in both UPPE and CPPE. Tetradecanoylphorbol Acetate 62-65 vascular endothelial growth factor A Homo sapiens 0-4 24335179-0 2013 Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells. Tetradecanoylphorbol Acetate 21-24 vascular endothelial growth factor A Homo sapiens 82-86 24335179-3 2013 Here, we investigated the effect of BBR on TPA-induced VEGF and fibronectin (FN) as well as VEGF-induced FN in breast cancer cells. Tetradecanoylphorbol Acetate 43-46 vascular endothelial growth factor A Homo sapiens 55-59 24335179-7 2013 RESULTS: Our results showed that TPA, a tumor promoter, significantly increased the level of VEGF and FN expression in both MCF7 and T47D breast cancer cells. Tetradecanoylphorbol Acetate 33-36 vascular endothelial growth factor A Homo sapiens 93-97 24335179-8 2013 On the other hand, TPA-induced VEGF and FN expression was suppressed by LY294002, a PI-3K inhibitor. Tetradecanoylphorbol Acetate 19-22 vascular endothelial growth factor A Homo sapiens 31-35 24335179-10 2013 We also found that TPA-induced VEGF and FN expression was decreased by BBR treatment. Tetradecanoylphorbol Acetate 19-22 vascular endothelial growth factor A Homo sapiens 31-35 24335179-12 2013 CONCLUSION: Taken together, we suggest that BBR may suppress TPA-induced VEGF and FN as well as VEGF-induced FN through the inhibition of the PI-3K/AKT pathway in breast cancer cells. Tetradecanoylphorbol Acetate 61-64 vascular endothelial growth factor A Homo sapiens 73-77 19910455-6 2010 Whereas TPA or TGF-beta alone stimulated VEGF promoter activity and up-regulated mRNA levels, significant protein secretion was detected only after RA was added to the culture systems. Tetradecanoylphorbol Acetate 8-11 vascular endothelial growth factor A Homo sapiens 41-45 22773582-0 2012 Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-kappaB pathway in hepatocellular carcinoma cells. Tetradecanoylphorbol Acetate 19-22 vascular endothelial growth factor A Homo sapiens 41-45 22773582-4 2012 TPA increased the NF-kappaB activity and the expressions of MMP-9 and VEGF significantly, but its effects were suppressed by sorafenib in a dose-dependent manner. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Homo sapiens 70-74 22773582-6 2012 Furthermore, transfection of Huh7 cell with an inhibitor of kappaB-alpha mutant vector, led to reduced TPA-induced MMP-9 and VEGF mRNA expressions. Tetradecanoylphorbol Acetate 103-106 vascular endothelial growth factor A Homo sapiens 125-129 22773582-7 2012 Sorafenib inhibits TPA-induced MMP-9 and VEGF expressions via the suppression of ERK/NF-kappaB pathway in HCC cells. Tetradecanoylphorbol Acetate 19-22 vascular endothelial growth factor A Homo sapiens 41-45 22548401-3 2012 The release of VEGF-A by Human MCs-1 (HMC-1) was induced by calcium ionophore A23187 and phorbol 12 myristate 13 acetate (PMA). Tetradecanoylphorbol Acetate 89-120 vascular endothelial growth factor A Homo sapiens 15-21 22548401-3 2012 The release of VEGF-A by Human MCs-1 (HMC-1) was induced by calcium ionophore A23187 and phorbol 12 myristate 13 acetate (PMA). Tetradecanoylphorbol Acetate 122-125 vascular endothelial growth factor A Homo sapiens 15-21 21480395-10 2011 We also performed ELISAs and discovered significant up-regulation of IL-8 and VEGF secretion by UMSCC 11A after treatment with phorbol 12-myristate 13-acetate, tumor necrosis factor alpha, and CSC, which was down-regulated by the A-Fos dominant negative protein. Tetradecanoylphorbol Acetate 127-158 vascular endothelial growth factor A Homo sapiens 78-82 21173077-2 2011 We have shown that retinoic acid (RA), which is known to play a necessary role in early events in pregnancy, can combine with transcriptional activators of VEGF (e.g. TPA, TGF-beta, IL-1beta) to rapidly induce VEGF secretion from human endometrial stromal cells through a translational mechanism of action. Tetradecanoylphorbol Acetate 167-170 vascular endothelial growth factor A Homo sapiens 156-160 21173077-5 2011 Importantly, co-treatment of RA with TPA or TGF-beta further stimulated ROS production in a fashion that positively correlated with levels of VEGF secretion. Tetradecanoylphorbol Acetate 37-40 vascular endothelial growth factor A Homo sapiens 142-146 20696233-7 2010 Furthermore, butein repressed the expression of VEGF and MMP-9 induced by treatment with tumor necrosis factor-alpha and phorbol-12-myristate-13-acetate. Tetradecanoylphorbol Acetate 121-152 vascular endothelial growth factor A Homo sapiens 48-52 19910455-9 2010 Although the precise mechanism(s) of the RA effect remains to be defined, it appears to be mediated by reactive oxygen species; the antioxidant N-acetylcysteine inhibited RA+TPA-stimulated secretion of VEGF by more than 80%. Tetradecanoylphorbol Acetate 174-177 vascular endothelial growth factor A Homo sapiens 202-206 19181503-4 2009 To investigate the regulatory mechanism of silibinin on TPA-induced MMP-9 and VEGF expression, we pretreated cells with various inhibitors, such as UO126 (MEK1/2 inhibitor), SP600125 (JNK inhibitor), and SB203580 (p38 inhibitor). Tetradecanoylphorbol Acetate 56-59 vascular endothelial growth factor A Homo sapiens 78-82 19857463-3 2009 The megakaryocytic differentiation of UT-7/TPO cells on treatment with phorbol myristate acetate (PMA) was accompanied by a marked up-regulation of NRP-1 mRNA and protein expression and by an increase in VEGF-binding activity, which was mainly mediated by VEGFR-2. Tetradecanoylphorbol Acetate 71-96 vascular endothelial growth factor A Homo sapiens 204-208 19857463-3 2009 The megakaryocytic differentiation of UT-7/TPO cells on treatment with phorbol myristate acetate (PMA) was accompanied by a marked up-regulation of NRP-1 mRNA and protein expression and by an increase in VEGF-binding activity, which was mainly mediated by VEGFR-2. Tetradecanoylphorbol Acetate 98-101 vascular endothelial growth factor A Homo sapiens 204-208 19181503-2 2009 Herein, we investigated the effect of silibinin, a major constituent (flavanolignan) of the fruits of Silybum marianum, on 12-O-tetradecanoyl phorbol-13-acetate (TPA)-induced MMP-9 and VEGF expression in MCF-7 human breast cancer cells. Tetradecanoylphorbol Acetate 123-160 vascular endothelial growth factor A Homo sapiens 185-189 19181503-3 2009 The expression of MMP-9 and VEGF in response to TPA was increased, whereas TPA-induced MMP-9 and VEGF expression was decreased by silibinin. Tetradecanoylphorbol Acetate 48-51 vascular endothelial growth factor A Homo sapiens 28-32 19181503-3 2009 The expression of MMP-9 and VEGF in response to TPA was increased, whereas TPA-induced MMP-9 and VEGF expression was decreased by silibinin. Tetradecanoylphorbol Acetate 75-78 vascular endothelial growth factor A Homo sapiens 97-101 19919521-6 2009 Treatment of neutrophils with phorbol myristate acetate (PMA), N-Formyl-Met-Leu-Phe (fMLP) and tumor necrosis factor-alpha (TNF-alpha) induced VEGF release. Tetradecanoylphorbol Acetate 30-55 vascular endothelial growth factor A Homo sapiens 143-147 19919521-6 2009 Treatment of neutrophils with phorbol myristate acetate (PMA), N-Formyl-Met-Leu-Phe (fMLP) and tumor necrosis factor-alpha (TNF-alpha) induced VEGF release. Tetradecanoylphorbol Acetate 57-60 vascular endothelial growth factor A Homo sapiens 143-147 19447859-5 2009 In addition, pterostilbene can inhibit TPA-induced expression of vascular endothelial growth factor, epidermal growth factor and epidermal growth factor receptor. Tetradecanoylphorbol Acetate 39-42 vascular endothelial growth factor A Homo sapiens 65-99 19181503-8 2009 TPA-induced VEGF expression was also suppressed by UO126. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Homo sapiens 12-16 19181503-10 2009 Taken together, we suggest that the inhibition of TPA-induced MMP-9 and VEGF expression by silibinin is mediated by the suppression of the Raf/MEK/ERK pathway in MCF-7 breast cancer cells. Tetradecanoylphorbol Acetate 50-53 vascular endothelial growth factor A Homo sapiens 72-76 18261985-2 2008 In the VEGF family, both mRNA and protein expression of VEGF-C were up-regulated in phorbol myristate acetate (PMA)-differentiated HL-60 cells. Tetradecanoylphorbol Acetate 84-109 vascular endothelial growth factor A Homo sapiens 7-11 18056764-9 2008 PMA-induced tube formation was reduced by inhibition of the VEGF receptor kinase, or by VEGF knockdown. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Homo sapiens 60-64 18056764-9 2008 PMA-induced tube formation was reduced by inhibition of the VEGF receptor kinase, or by VEGF knockdown. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Homo sapiens 88-92 18261985-2 2008 In the VEGF family, both mRNA and protein expression of VEGF-C were up-regulated in phorbol myristate acetate (PMA)-differentiated HL-60 cells. Tetradecanoylphorbol Acetate 111-114 vascular endothelial growth factor A Homo sapiens 7-11 15643507-5 2005 Cells were also treated with phorbol 12-myristate 13-acetate (PMA) to study enhanced MMP and VEGF expression. Tetradecanoylphorbol Acetate 62-65 vascular endothelial growth factor A Homo sapiens 93-97 17512973-4 2007 Accordingly, VEGF-induced fibrinolysis correlated with an increase in the expression of tPA and of some MMPs, such as MT2-MMP and was completely blocked by a neutralizing antibody against tPA. Tetradecanoylphorbol Acetate 88-91 vascular endothelial growth factor A Homo sapiens 13-17 17512973-4 2007 Accordingly, VEGF-induced fibrinolysis correlated with an increase in the expression of tPA and of some MMPs, such as MT2-MMP and was completely blocked by a neutralizing antibody against tPA. Tetradecanoylphorbol Acetate 188-191 vascular endothelial growth factor A Homo sapiens 13-17 16306087-0 2006 Antagonistic functions of tetradecanoyl phorbol acetate-inducible-sequence 11b and HuR in the hormonal regulation of vascular endothelial growth factor messenger ribonucleic acid stability by adrenocorticotropin. Tetradecanoylphorbol Acetate 26-55 vascular endothelial growth factor A Homo sapiens 117-151 16306087-4 2006 We further demonstrated that the zinc finger RNA-binding protein Tis11b (tetradecanoyl phorbol acetate-inducible-sequence 11b) destabilizes VEGF mRNA through its 3"-untranslated region (3"-UTR) and that Tis11b is involved in the decay phase of ACTH-induced VEGF mRNA expression. Tetradecanoylphorbol Acetate 73-102 vascular endothelial growth factor A Homo sapiens 140-144 16306087-4 2006 We further demonstrated that the zinc finger RNA-binding protein Tis11b (tetradecanoyl phorbol acetate-inducible-sequence 11b) destabilizes VEGF mRNA through its 3"-untranslated region (3"-UTR) and that Tis11b is involved in the decay phase of ACTH-induced VEGF mRNA expression. Tetradecanoylphorbol Acetate 73-102 vascular endothelial growth factor A Homo sapiens 257-261 12558054-8 2002 Incubation with A23187 in association with PMA produced the same increase in arachidonate as the VEGF treatment. Tetradecanoylphorbol Acetate 43-46 vascular endothelial growth factor A Homo sapiens 97-101 15144607-7 2004 (3) There was a positive correlation between the positive rate of nucleolar staining for NF-kappaB p65, the relative expression of VEGF protein and the percentage of G(2)/M phases of cell cycle in hypoxia PMA group (r = 0.587 - 0.710, P < 0.05, respectively). Tetradecanoylphorbol Acetate 205-208 vascular endothelial growth factor A Homo sapiens 131-135 13679066-3 2003 Phorbol 12-myristate 13-acetate (PMA), a non-specific activator of PKC, induced VEGF secretion by glioma cells, which was enhanced by calcium ionophore A23187, but completely blocked after prolonged treatment of cells with 1 microM PMA, by presumably depleting PKC. Tetradecanoylphorbol Acetate 0-31 vascular endothelial growth factor A Homo sapiens 80-84 13679066-3 2003 Phorbol 12-myristate 13-acetate (PMA), a non-specific activator of PKC, induced VEGF secretion by glioma cells, which was enhanced by calcium ionophore A23187, but completely blocked after prolonged treatment of cells with 1 microM PMA, by presumably depleting PKC. Tetradecanoylphorbol Acetate 33-36 vascular endothelial growth factor A Homo sapiens 80-84 13679066-3 2003 Phorbol 12-myristate 13-acetate (PMA), a non-specific activator of PKC, induced VEGF secretion by glioma cells, which was enhanced by calcium ionophore A23187, but completely blocked after prolonged treatment of cells with 1 microM PMA, by presumably depleting PKC. Tetradecanoylphorbol Acetate 232-235 vascular endothelial growth factor A Homo sapiens 80-84 15289320-3 2004 This cyclopentenone was able to inhibit activator protein1 (AP-1)-dependent transcriptional induction of COX-2 and VEGF promoters induced by phorbol 12-myristate 13-acetate (PMA) or c-Jun overexpression. Tetradecanoylphorbol Acetate 141-172 vascular endothelial growth factor A Homo sapiens 115-119 15289320-3 2004 This cyclopentenone was able to inhibit activator protein1 (AP-1)-dependent transcriptional induction of COX-2 and VEGF promoters induced by phorbol 12-myristate 13-acetate (PMA) or c-Jun overexpression. Tetradecanoylphorbol Acetate 174-177 vascular endothelial growth factor A Homo sapiens 115-119 15288477-5 2004 This effect of VEGF was mimicked by phorbol-12-myristate-13-acetate (PMA) and was sensitive to protein kinase C (PKC) inhibition by Go6850. Tetradecanoylphorbol Acetate 36-67 vascular endothelial growth factor A Homo sapiens 15-19 15288477-5 2004 This effect of VEGF was mimicked by phorbol-12-myristate-13-acetate (PMA) and was sensitive to protein kinase C (PKC) inhibition by Go6850. Tetradecanoylphorbol Acetate 69-72 vascular endothelial growth factor A Homo sapiens 15-19 12960735-6 2003 For the inhibition of basic fibroblast growth factor (bFGF)-, vascular endothelial growth factor (VEGF)- or beta-phorbol 12-myristate-13-acetate (PMA)-induced endothelial cell proliferation or endothelial cell adhesion to fibronectin, TMZ concentrations of at least 25 microM were necessary, indicating that bFGF-, VEGF- or protein kinase C-mediated pathways may not primarily be involved in the observed antiangiogenic effect. Tetradecanoylphorbol Acetate 146-149 vascular endothelial growth factor A Homo sapiens 315-320 12119537-7 2002 We found that U. urealyticum antigen (>/=4 x 10(7) color-changing units/ml) stimulated human macrophages (phorbol 12-myristate 13-acetate-differentiated THP-1 cell line) to produce VEGF and soluble ICAM-1 in a dose-dependent manner (p < 0.05) measured by ELISA. Tetradecanoylphorbol Acetate 109-140 vascular endothelial growth factor A Homo sapiens 184-188 12117969-4 2002 Vascular endothelial growth factor (VEGF), a direct inducer of angiogenesis, and interleukin-1beta (IL-1beta), a potentiator of VEGF, were detected within 12 and 6 h, respectively, in supernatants from phorbol 12-myristate 13-acetate-differentiated human THP-1 macrophages exposed to live B. henselae. Tetradecanoylphorbol Acetate 202-233 vascular endothelial growth factor A Homo sapiens 0-34 12377207-5 2002 VEGF-induced Akt activation was prevented by down-regulation of PKC induced by prolonged pretreatment with the phorbol ester, PMA. Tetradecanoylphorbol Acetate 126-129 vascular endothelial growth factor A Homo sapiens 0-4 10235536-12 1999 Nitric oxide was also effective at suppressing increased VEGF expression secondan, to mutant ras and TPA. Tetradecanoylphorbol Acetate 101-104 vascular endothelial growth factor A Homo sapiens 57-61 11766607-5 2001 RESULTS: 100 ng/ml PMA significantly increased VEGF mRNA expression, intracellular production and secretion of VEGF in endothelial cells, while triptolide inhibited the effects of PMA in a dose-dependent manner. Tetradecanoylphorbol Acetate 19-22 vascular endothelial growth factor A Homo sapiens 47-51 11766607-5 2001 RESULTS: 100 ng/ml PMA significantly increased VEGF mRNA expression, intracellular production and secretion of VEGF in endothelial cells, while triptolide inhibited the effects of PMA in a dose-dependent manner. Tetradecanoylphorbol Acetate 19-22 vascular endothelial growth factor A Homo sapiens 111-115 11480589-5 2001 VEGF mRNA expression and protein secretion were found to be enhanced by phorbol 12-myristate 13-acetate. Tetradecanoylphorbol Acetate 72-103 vascular endothelial growth factor A Homo sapiens 0-4 11158990-7 2001 ACE induction by VEGF was inhibited by the selective protein kinase C (PKC) inhibitor GF109203X (2.5 x 10(-3) mmol/l) and by downregulating PKC with phorbol 12-myristate 13-acetate. Tetradecanoylphorbol Acetate 149-180 vascular endothelial growth factor A Homo sapiens 17-21 10924082-6 2000 However, stimulation of platelets with thrombin and of PMN with phorbol 12-myristate 13-acetate induced a time-dependent release of VEGF, peaking after 30 and 60 min, respectively. Tetradecanoylphorbol Acetate 64-95 vascular endothelial growth factor A Homo sapiens 132-136 10617662-2 2000 Experimentally, VEGF overexpression can be induced by the treatment of cell cultures and biological tissues with phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA). Tetradecanoylphorbol Acetate 137-173 vascular endothelial growth factor A Homo sapiens 16-20 10617662-2 2000 Experimentally, VEGF overexpression can be induced by the treatment of cell cultures and biological tissues with phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA). Tetradecanoylphorbol Acetate 175-178 vascular endothelial growth factor A Homo sapiens 16-20 10617662-6 2000 Because the VEGF promoter contains four potential AP1 binding sites, we used different promoter constructs to identify the functional site responsible for TPA induction and retinoid inhibition. Tetradecanoylphorbol Acetate 155-158 vascular endothelial growth factor A Homo sapiens 12-16 10336429-3 1999 Here we report that when protein kinase C (PKC) pathways were activated in human glioblastoma U373 cells by phorbol 12-myristate 13-acetate (PMA), VEGF mRNA expression was up-regulated via a post-transcriptional mRNA stabilization mechanism. Tetradecanoylphorbol Acetate 108-139 vascular endothelial growth factor A Homo sapiens 147-151 11483411-2 2001 In this study, we investigated the effect of the phorbol 12-myristate 13-acetate (PMA) on the expression of VEGF in human bladder transitional carcinoma cells (RT4). Tetradecanoylphorbol Acetate 49-80 vascular endothelial growth factor A Homo sapiens 108-112 11483411-2 2001 In this study, we investigated the effect of the phorbol 12-myristate 13-acetate (PMA) on the expression of VEGF in human bladder transitional carcinoma cells (RT4). Tetradecanoylphorbol Acetate 82-85 vascular endothelial growth factor A Homo sapiens 108-112 11749832-3 2001 The effects of triptolide on VEGF mRNA expression, production, and secretion induced by 12-o-tetradecanoyl-phorbol-13-acetate (TPA) were measured by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR), flow cytometry, and enzyme linked immunosorbent assay (ELISA) respectively. Tetradecanoylphorbol Acetate 88-125 vascular endothelial growth factor A Homo sapiens 29-33 11749832-3 2001 The effects of triptolide on VEGF mRNA expression, production, and secretion induced by 12-o-tetradecanoyl-phorbol-13-acetate (TPA) were measured by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR), flow cytometry, and enzyme linked immunosorbent assay (ELISA) respectively. Tetradecanoylphorbol Acetate 127-130 vascular endothelial growth factor A Homo sapiens 29-33 11749832-5 2001 RESULTS: VEGF mRNA expression was markedly up-regulated by TPA-stimulation. Tetradecanoylphorbol Acetate 59-62 vascular endothelial growth factor A Homo sapiens 9-13 11749832-6 2001 In addition, the production and secretion of VEGF in endothelial cells also increased in TPA treated cells. Tetradecanoylphorbol Acetate 89-92 vascular endothelial growth factor A Homo sapiens 45-49 11749832-7 2001 It was founded that triptolide inhibited VEGF mRNA expression, protein production and secretion in endothelial cells induced by TPA. Tetradecanoylphorbol Acetate 128-131 vascular endothelial growth factor A Homo sapiens 41-45 9354686-3 1997 The present work shows that phorbol-12-myristate 13-acetate (PMA), fMet-Leu-Phe, and tumor necrosis factor-alpha (TNF-alpha) triggered a time-dependent secretion of VEGF by human neutrophils. Tetradecanoylphorbol Acetate 28-59 vascular endothelial growth factor A Homo sapiens 165-169 9819353-7 1998 (4) VEGF was effective in preventing PMA-induced tube-like structure regression after PMA-withdrawal by (5) activating the mitogen activated protein kinase (MAPK), rather than the Akt/PKB, signaling pathway. Tetradecanoylphorbol Acetate 37-40 vascular endothelial growth factor A Homo sapiens 4-8 10084996-3 1999 Prevotella intermedia LPS, phorbol 12-myristate 13-acetate, and interleukin-6 also induced VEGF mRNA expression in HPC. Tetradecanoylphorbol Acetate 27-58 vascular endothelial growth factor A Homo sapiens 91-95 9453354-0 1998 Vascular endothelial growth factor mRNA in pericytes is upregulated by phorbol myristate acetate. Tetradecanoylphorbol Acetate 71-96 vascular endothelial growth factor A Homo sapiens 0-34 9453354-3 1998 The goal of the present study was to evaluate the effects of phorbol myristate acetate (PMA), a substance known to produce nonhydrostatic pulmonary edema in intact animals, on VEGF gene expression in pericyte cultures. Tetradecanoylphorbol Acetate 61-86 vascular endothelial growth factor A Homo sapiens 176-180 9453354-3 1998 The goal of the present study was to evaluate the effects of phorbol myristate acetate (PMA), a substance known to produce nonhydrostatic pulmonary edema in intact animals, on VEGF gene expression in pericyte cultures. Tetradecanoylphorbol Acetate 88-91 vascular endothelial growth factor A Homo sapiens 176-180 9354686-5 1997 Because the extracellular content of VEGF in human neutrophils supernatants remained constant over a period of 2 to 24 hours and because PMA is a potent inducer of human neutrophil degranulation, the PMA-induced secretion of VEGF may be due to a pre-existing intracellular pool of this molecule. Tetradecanoylphorbol Acetate 137-140 vascular endothelial growth factor A Homo sapiens 37-41 9354686-5 1997 Because the extracellular content of VEGF in human neutrophils supernatants remained constant over a period of 2 to 24 hours and because PMA is a potent inducer of human neutrophil degranulation, the PMA-induced secretion of VEGF may be due to a pre-existing intracellular pool of this molecule. Tetradecanoylphorbol Acetate 200-203 vascular endothelial growth factor A Homo sapiens 37-41 9354686-5 1997 Because the extracellular content of VEGF in human neutrophils supernatants remained constant over a period of 2 to 24 hours and because PMA is a potent inducer of human neutrophil degranulation, the PMA-induced secretion of VEGF may be due to a pre-existing intracellular pool of this molecule. Tetradecanoylphorbol Acetate 200-203 vascular endothelial growth factor A Homo sapiens 225-229 9354686-8 1997 A dosedependent inhibition of PMA-induced VEGF secretion was observed when the cells were incubated in the presence of pentoxifylline, a methylxanthine known to inhibit neutrophil degranulation. Tetradecanoylphorbol Acetate 30-33 vascular endothelial growth factor A Homo sapiens 42-46 9354686-3 1997 The present work shows that phorbol-12-myristate 13-acetate (PMA), fMet-Leu-Phe, and tumor necrosis factor-alpha (TNF-alpha) triggered a time-dependent secretion of VEGF by human neutrophils. Tetradecanoylphorbol Acetate 61-64 vascular endothelial growth factor A Homo sapiens 165-169 9342371-6 1997 001), returning to the baseline by 24 h. Stretch-induced VPF secretion was partially prevented both by the protein kinase C (PKC) inhibitor H7 (50 microM: 72% inhibition, P < 0.05) and by pretreatment with phorbol ester (phorbol-12-myristate-13 acetate 10(-)7 M: 77% inhibition, P < 0.05). Tetradecanoylphorbol Acetate 224-255 vascular endothelial growth factor A Homo sapiens 57-60 7615975-3 1995 Transforming growth factor-alpha, epidermal growth factor, and phorbol myristate acetate markedly stimulated VPF/VEGF mRNA expression by cultured keratinocytes; as in psoriatic skin, the three most common VPF/VEGF isoforms (encoding proteins of 121, 165, and 189 amino acids) were upregulated to an equal extent. Tetradecanoylphorbol Acetate 63-88 vascular endothelial growth factor A Homo sapiens 109-112 8841458-5 1996 However, TPA markedly enhanced the expression of 121-, 165- and 189-amino-acid-containing isoforms of VPF/VEGF mRNA in T cells. Tetradecanoylphorbol Acetate 9-12 vascular endothelial growth factor A Homo sapiens 102-105 8841458-5 1996 However, TPA markedly enhanced the expression of 121-, 165- and 189-amino-acid-containing isoforms of VPF/VEGF mRNA in T cells. Tetradecanoylphorbol Acetate 9-12 vascular endothelial growth factor A Homo sapiens 106-110 8841458-6 1996 Both CD4+ and CD8+ T cells expressed VPF/VEGF mRNA in response to TPA treatment. Tetradecanoylphorbol Acetate 66-69 vascular endothelial growth factor A Homo sapiens 37-40 8841458-6 1996 Both CD4+ and CD8+ T cells expressed VPF/VEGF mRNA in response to TPA treatment. Tetradecanoylphorbol Acetate 66-69 vascular endothelial growth factor A Homo sapiens 41-45 8537383-6 1995 Phorbol-12-myristate 13-acetate (10(-7) M) treatment, however, induced VEGF mRNA expression in both HUVECs and HMECs, peaking at 3 and 6 h, respectively, and returning to undetectable levels by 12 h. In vitro exposure of HUVECs to a hypoxic environment (pO2 = 35 mm of mercury) for 12, 24, and 48 h and exposure of HMECs for 6, 12, 24, and 48 h induced VEGF mRNA in a time-dependent fashion. Tetradecanoylphorbol Acetate 0-31 vascular endothelial growth factor A Homo sapiens 71-75 8537383-6 1995 Phorbol-12-myristate 13-acetate (10(-7) M) treatment, however, induced VEGF mRNA expression in both HUVECs and HMECs, peaking at 3 and 6 h, respectively, and returning to undetectable levels by 12 h. In vitro exposure of HUVECs to a hypoxic environment (pO2 = 35 mm of mercury) for 12, 24, and 48 h and exposure of HMECs for 6, 12, 24, and 48 h induced VEGF mRNA in a time-dependent fashion. Tetradecanoylphorbol Acetate 0-31 vascular endothelial growth factor A Homo sapiens 353-357 7615975-3 1995 Transforming growth factor-alpha, epidermal growth factor, and phorbol myristate acetate markedly stimulated VPF/VEGF mRNA expression by cultured keratinocytes; as in psoriatic skin, the three most common VPF/VEGF isoforms (encoding proteins of 121, 165, and 189 amino acids) were upregulated to an equal extent. Tetradecanoylphorbol Acetate 63-88 vascular endothelial growth factor A Homo sapiens 113-117 7615975-3 1995 Transforming growth factor-alpha, epidermal growth factor, and phorbol myristate acetate markedly stimulated VPF/VEGF mRNA expression by cultured keratinocytes; as in psoriatic skin, the three most common VPF/VEGF isoforms (encoding proteins of 121, 165, and 189 amino acids) were upregulated to an equal extent. Tetradecanoylphorbol Acetate 63-88 vascular endothelial growth factor A Homo sapiens 205-208 7615975-3 1995 Transforming growth factor-alpha, epidermal growth factor, and phorbol myristate acetate markedly stimulated VPF/VEGF mRNA expression by cultured keratinocytes; as in psoriatic skin, the three most common VPF/VEGF isoforms (encoding proteins of 121, 165, and 189 amino acids) were upregulated to an equal extent. Tetradecanoylphorbol Acetate 63-88 vascular endothelial growth factor A Homo sapiens 209-213 7615975-4 1995 Transforming growth factor (TGF)-alpha, epidermal growth factor, and phorbol myristate acetate also enhanced the secretion of VPF/VEGF by keratinocytes; in contrast, a number of other cytokines including interleukin (IL)-1, IL-6, IL-8, tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta did not induce VPF/VEGF secretion. Tetradecanoylphorbol Acetate 69-94 vascular endothelial growth factor A Homo sapiens 126-129 7615975-4 1995 Transforming growth factor (TGF)-alpha, epidermal growth factor, and phorbol myristate acetate also enhanced the secretion of VPF/VEGF by keratinocytes; in contrast, a number of other cytokines including interleukin (IL)-1, IL-6, IL-8, tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta did not induce VPF/VEGF secretion. Tetradecanoylphorbol Acetate 69-94 vascular endothelial growth factor A Homo sapiens 130-134 7615975-4 1995 Transforming growth factor (TGF)-alpha, epidermal growth factor, and phorbol myristate acetate also enhanced the secretion of VPF/VEGF by keratinocytes; in contrast, a number of other cytokines including interleukin (IL)-1, IL-6, IL-8, tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta did not induce VPF/VEGF secretion. Tetradecanoylphorbol Acetate 69-94 vascular endothelial growth factor A Homo sapiens 334-337 7615975-4 1995 Transforming growth factor (TGF)-alpha, epidermal growth factor, and phorbol myristate acetate also enhanced the secretion of VPF/VEGF by keratinocytes; in contrast, a number of other cytokines including interleukin (IL)-1, IL-6, IL-8, tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta did not induce VPF/VEGF secretion. Tetradecanoylphorbol Acetate 69-94 vascular endothelial growth factor A Homo sapiens 338-342 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Tetradecanoylphorbol Acetate 35-71 vascular endothelial growth factor A Homo sapiens 92-96 8534863-4 1995 VEGF expression can be induced in various cell types by a number of stimuli including hypoxia, differentiation, growth factors and tumor promoters of the phorbol ester class, such as TPA. Tetradecanoylphorbol Acetate 183-186 vascular endothelial growth factor A Homo sapiens 0-4 8930020-5 1995 Here, we demonstrate that both hypoxia and TPA induce stabilization of VEGF mRNA, that stabilization by hypoxia is rapidly reversible upon reexposure to normoxia, and that tumor cell lines exhibiting constitutive overexpression of VEGF also exhibit constitutive stabilization of VEGF transcripts. Tetradecanoylphorbol Acetate 43-46 vascular endothelial growth factor A Homo sapiens 71-75 8930020-6 1995 Stabilized VEGF transcripts in tumor cells are refractile or nearly refractile toward further stabilization by TPA or hypoxia, respectively. Tetradecanoylphorbol Acetate 111-114 vascular endothelial growth factor A Homo sapiens 11-15 8108142-2 1994 Expression of the VEGF gene can be induced by tumor promoting phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA), which activate protein kinase C (PKC). Tetradecanoylphorbol Acetate 86-122 vascular endothelial growth factor A Homo sapiens 18-22 8108142-2 1994 Expression of the VEGF gene can be induced by tumor promoting phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA), which activate protein kinase C (PKC). Tetradecanoylphorbol Acetate 124-127 vascular endothelial growth factor A Homo sapiens 18-22 8108142-5 1994 Mutant p53 specifically increases TPA induction of VEGF without affecting the expression of other TPA inducible genes. Tetradecanoylphorbol Acetate 34-37 vascular endothelial growth factor A Homo sapiens 51-55 8108142-6 1994 TPA dependent VEGF expression is also enhanced by human p53 mutated at amino acid 175. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Homo sapiens 14-18 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Tetradecanoylphorbol Acetate 247-250 vascular endothelial growth factor A Homo sapiens 92-96 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Tetradecanoylphorbol Acetate 247-250 vascular endothelial growth factor A Homo sapiens 147-151 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Tetradecanoylphorbol Acetate 247-250 vascular endothelial growth factor A Homo sapiens 147-151 8304487-6 1994 Its physiological role might be the regulation of GEN proliferation, and the induction of VEGF expression by FBS and TPA suggests its involvement in the response of glomerular capillary endothelial cells to injury in certain pathophysiological states. Tetradecanoylphorbol Acetate 117-120 vascular endothelial growth factor A Homo sapiens 90-94 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Tetradecanoylphorbol Acetate 35-71 vascular endothelial growth factor A Homo sapiens 147-151 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Tetradecanoylphorbol Acetate 35-71 vascular endothelial growth factor A Homo sapiens 147-151 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Tetradecanoylphorbol Acetate 73-76 vascular endothelial growth factor A Homo sapiens 92-96 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Tetradecanoylphorbol Acetate 73-76 vascular endothelial growth factor A Homo sapiens 147-151 8304487-4 1994 The treatment of GEN with 10(-7) M 12-O-tetradecanoylphorbol-13-acetate (TPA) increased the VEGF mRNA abundance fivefold, supporting the idea that VEGF expression is regulated by protein kinase C. [3H]thymidine incorporation into GEN treated with TPA (10(-7) M) was inhibited by neutralizing antibody for VEGF. Tetradecanoylphorbol Acetate 73-76 vascular endothelial growth factor A Homo sapiens 147-151 8264155-7 1993 Fetal calf serum and 12-o-tetradecanoyl- phorbol-13-acetate (TPA) transiently enhanced VPF/VEGF mRNA expression in cultured human MC. Tetradecanoylphorbol Acetate 21-59 vascular endothelial growth factor A Homo sapiens 87-90 8264155-7 1993 Fetal calf serum and 12-o-tetradecanoyl- phorbol-13-acetate (TPA) transiently enhanced VPF/VEGF mRNA expression in cultured human MC. Tetradecanoylphorbol Acetate 21-59 vascular endothelial growth factor A Homo sapiens 91-95 8264155-7 1993 Fetal calf serum and 12-o-tetradecanoyl- phorbol-13-acetate (TPA) transiently enhanced VPF/VEGF mRNA expression in cultured human MC. Tetradecanoylphorbol Acetate 61-64 vascular endothelial growth factor A Homo sapiens 87-90 8264155-7 1993 Fetal calf serum and 12-o-tetradecanoyl- phorbol-13-acetate (TPA) transiently enhanced VPF/VEGF mRNA expression in cultured human MC. Tetradecanoylphorbol Acetate 61-64 vascular endothelial growth factor A Homo sapiens 91-95 8264155-9 1993 Dexamethasone (DEX) inhibited the TPA-induced increase in VPF/VEGF mRNA expression, whereas DEX did not change the basal level. Tetradecanoylphorbol Acetate 34-37 vascular endothelial growth factor A Homo sapiens 58-61 8264155-9 1993 Dexamethasone (DEX) inhibited the TPA-induced increase in VPF/VEGF mRNA expression, whereas DEX did not change the basal level. Tetradecanoylphorbol Acetate 34-37 vascular endothelial growth factor A Homo sapiens 62-66 8264155-10 1993 The DEX depressed the TPA-induced increase in VPF/VEGF mRNA expression is therefore probably a result of transcriptional control. Tetradecanoylphorbol Acetate 22-25 vascular endothelial growth factor A Homo sapiens 46-49 8264155-10 1993 The DEX depressed the TPA-induced increase in VPF/VEGF mRNA expression is therefore probably a result of transcriptional control. Tetradecanoylphorbol Acetate 22-25 vascular endothelial growth factor A Homo sapiens 50-54 8264155-12 1993 TPA increased VPF/VEGF protein levels as well as those of VPF/VEGF mRNA in cultured human MC. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Homo sapiens 14-17 8264155-12 1993 TPA increased VPF/VEGF protein levels as well as those of VPF/VEGF mRNA in cultured human MC. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Homo sapiens 18-22 1719968-5 1991 Phorbol 12-myristate 13-acetate, a potent inducer of the differentiation of U937 cells, caused a 12.5-fold increase in VPF mRNA levels at 24 hours, coinciding with the differentiation of these monocyte-like cells into macrophage-like cells. Tetradecanoylphorbol Acetate 0-31 vascular endothelial growth factor A Homo sapiens 119-122 1711045-8 1991 The promoter region also contains several potential binding sites for the transcription factors AP-1 and AP-2; consistent with the presence of these sites, Northern blot analysis demonstrated that the level of VEGF transcripts is elevated in cultured vascular smooth muscle cells after treatment with the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate. Tetradecanoylphorbol Acetate 319-356 vascular endothelial growth factor A Homo sapiens 210-214